High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Mortensen, Mørck ^a   Høyer, Søren ^a   Ørntoft, Falck ^a   Sørensen, Dalsgaard ^a   Dyrskjøt, Lars ^a   Borre, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Biochemical recurrence; Biomarker; microRNA; miR 449; Prostate cancer; Prostatectomy

Indexed keywords

MICRORNA; MICRORNA 449B; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MIRN449 MICRORNA, HUMAN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; QUANTITATIVE ANALYSIS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; RNA ANALYSIS; VALIDATION STUDY; CANCER GRADING; CANCER STAGING; COHORT ANALYSIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; RECURRENT DISEASE; REPRODUCIBILITY;

AGED; BIOMARKERS; COHORT STUDIES; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; REPRODUCIBILITY OF RESULTS;

EID: 84924408128     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-859     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2008,2010(127):2893-2917.
2. Gosselaar C, Roobol MJ, Schroder FH: Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant? BJU Int 2005, 95:231-237. 10.1111/j.1464-410X.2005.05324.x
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A, ERSPC Investigators: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328. 10.1056/NEJMoa0810084
4. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L: Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol 2012, 62:204-209. 10.1016/j.eururo.2012.04.024
5. Klotz L: Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013, 14:97-108. 10.1007/s11864-012-0221-5
6. Ahmed FE: Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn 2007, 7:569-603. 10.1586/14737159.7.5.569
7. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9
8. Hammond SM: MicroRNAs as oncogenes. Curr Opin Genet Dev 2006, 16:4-9. 10.1016/j.gde.2005.12.005
9. Kent OA, Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25:6188-6196. 10.1038/sj.onc.1209913
10. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM: MicroRNA expression and function in cancer. Trends Mol Med 2006, 12:580-587. 10.1016/j.molmed.2006.10.006
11. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006. 10.1038/cr.2008.282
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518. 10.1073/pnas.0804549105
13. Bryant RJ1, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC: Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012, 106:768-774. 10.1038/bjc.2011.595
14. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sültmann H: Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2011, 128:608-616. 10.1002/ijc.25376
15. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008, 27:1788-1793. 10.1038/sj.onc.1210809
16. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170. 10.1158/0008-5472.CAN-08-0144
17. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T: MicroRNA expression profiling in prostate cancer. Cancer Res 2007, 67:6130-6135. 10.1158/0008-5472.CAN-07-0533
18. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010, 126:1166-1176.
19. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J: MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009, 16:206-216.
20. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, Lee DH, Stephens RM, Liu CG, Calin GA, Croce CM, Ambs S: Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 2008, 68:1152-1164. 10.1002/pros.20786
21. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, Riedmiller H, Kneitz B: Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010, 127:394-403.
22. Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K, Yousef GM: miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. Int J Oncol 2011, 39:1183-1192.
23. Coppola V, De MR, Bonci D: MicroRNAs and prostate cancer. Endocr Relat Cancer 2010, 17:F1-F17. 10.1677/ERC-09-0172
24. Heebøll S, Borre M, Ottosen PD, Andersen CL, Mansilla F, Dyrskjøt L, Orntoft TF, Tørring N: SMARCC1 expression is upregulated in prostate cancer and positively correlated with tumour recurrence and dedifferentiation. Histol Histopathol 2008, 23:1069-1076.
25. Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Høyer S, Orntoft TF, Sørensen KD: DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. J Clin Oncol 2013, 31:3250-3258. 10.1200/JCO.2012.47.1847
26. Chen Y, Gelfond JA, McManus LM, Shireman PK: Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics 2009, 10:407. 10.1186/1471-2164-10-407
27. Yang X, Feng M, Jiang X, Wu Z, Li Z, Aau M, Yu Q: miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 2009, 23:2388-2393. 10.1101/gad.1819009
28. Lize M, Pilarski S, Dobbelstein M: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 2010, 17:452-458. 10.1038/cdd.2009.188
29. Noonan EJ1, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1724. 10.1038/onc.2009.19
30. Noonan EJ, Place RF, Basak S, Pookot D, Li LC: miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 2010, 1:349-358.
31. Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, Luo YJ, Liang PZ, Yang XQ, He JX, Zhang BL: Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells. Cancer Lett 2013, 344:195-203.
32. Paik S, Jung HS, Lee S, Yoon DS, Park MS, Lee JW: miR-449a regulates the chondrogenesis of human mesenchymal stem cells through direct targeting of lymphoid enhancer-binding factor-1. Stem Cells Dev 2012, 21:3298-3308. 10.1089/scd.2011.0732
33. Chesire DR, Ewing CM, Gage WR, Isaacs WB: In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002, 21:2679-2694. 10.1038/sj.onc.1205352
34. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB: Detection and analysis of beta-catenin mutations in prostate cancer. Prostate 2000, 45:223-234.
35. Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012, 4:a008052.
36. Noh T, Gabet Y, Cogan J, Shi Y, Tank A, Sasaki T, Criswell B, Dixon A, Lee C, Tam J, Kohler T, Segev E, Kockeritz L, Woodgett J, Müller R, Chai Y, Smith E, Bab I, Frenkel B: Lef1 haploinsufficient mice display a low turnover and low bone mass phenotype in a gender- and age-specific manner. PLoS One 2009, 4:e5438. 10.1371/journal.pone.0005438
37. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R: Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006, 99:402-410. 10.1002/jcb.20983
38. Marcet B, Chevalier B, Luxardi G, Coraux C, Zaragosi LE, Cibois M, Robbe-Sermesant K, Jolly T, Cardinaud B, Moreilhon C, Giovannini-Chami L, Nawrocki-Raby B, Birembaut P, Waldmann R, Kodjabachian L, Barbry P: Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol 2011, 13:693-699.